Why Shattuck Labs, Inc.’s (STTK) Stock Is Up 6.15%
As of Tuesday, October 20, Shattuck Labs, Inc.’s STTK share price has surged by 6.15%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Commentary & Analysis
Why Shattuck Labs, Inc.’s (STTK) Stock Is Down 7.00%
As of Tuesday, October 06, Shattuck Labs, Inc.’s STTK share price has dipped by 7.00%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Shattuck Labs, Inc.’s (STTK) Stock Is Down 5.05%
As of Monday, October 05, Shattuck Labs, Inc.’s STTK share price has dipped by 5.05%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Shattuck Labs, Inc.’s (STTK) Stock Is Up 5.28%
As of Thursday, October 01, Shattuck Labs, Inc.’s STTK share price has surged by 5.28%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Shattuck Labs, Inc.’s (STTK) Stock Is Up 9.94%
As of Wednesday, September 30, Shattuck Labs, Inc.’s STTK share price has surged by 9.94%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | STTK | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $579.1 | $227.8 | 39% |
|
| Shares Out (Mil) | 129.8 | 53.4 | 68% |
|
| Institutional Ownership | 89.1% | 92.9% | 57% |
|
| Float (Mil) | 67.8 | 41.2 | 53% |
|
| Beta | 1.10 | 0.95 | 65% |
|
| Avg Daily Volume (000s) | 967 | 513 | 70% |
|
| Price Change (52-week) |
200.5% | 47.3% | 99% |
|
| Growth | STTK | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (36.8%) | 12.8% | 1% |
|
| Net Income (5yr) | (5.9%) | (10.1%) | 33% |
|
| EPS (5yr) | 21.6% | 15.8% | 71 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (14.9%) | (15.7%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 11 | |
| Current EPS | ($0.105) | ($0.480) | ($0.517) | |
| Month Ago EPS | ($0.107) | ($0.477) | ($0.525) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.116) | ($0.476) | ($0.498) | |
| Year/Year Chg | (10.3%) | (31.5%) | (19.1%) | |
| Financials | STTK | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 2% |
|
| Net Income (TTM) (Mil) | ($53) | ($44) | 16% |
|
| EPS (TTM) | ($0.501) | ($1.500) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($41) | ($34) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $13 | $2 | 58% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 19% |
|
| Enterprise Value (Q1) (Mil) | $398 | $177 | 32% |
|
| Valuation | STTK | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.75 | 2.22 | 65% |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | STTK | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (36.9%) | (47.1%) | 15% |
|
| ROE | (39.2%) | (53.3%) | 18% |
|
| Liabilities to Assets | 4.3% | 29.3% | 2% |
|
| F-Score | 3 | 2 | 18% |
|
Shattuck Labs, Inc. did not pass any screens on 10/27/2026.
